Hyderabad, June 23 : Dr. Reddy’s Laboratories, a global pharmaceutical company, on Friday announced its entry into the trade generics business in India with the launch of its new dedicated division ‘RGenX’.
Through this, the company aims to provide patients with access to a wider range of products and increased affordability.
The new business will further the company’s goal of reaching over 1.5 billion patients by 2030, Hyderabad-based Pharma giant said in a release here.
Aiming to roll out its trade generics across cities and towns in India, including rural areas, the pharma company will work closely with its channel partners to ensure availability of its products.
M.V. Ramana, Chief Executive Officer, India and Emerging Markets, said: “This foray into trade generics will add to our reach and depth by making high-quality medicines accessible to more patients around the country”.
Follow our WhatsApp channel
